← Eichor
Study identifier: NCT05461664 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA

Condition: Gastrointestinal Stromal Tumors · Unresectable Solid Tumor · Recurrent Metastatic Malignant Neoplasm  ·  Sponsor: Xinhua Zhang, MD

PhaseN/A
Planned participants74
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a prospective, multicenter, observational real-world study to explore the Avapritinib therapy in GIST patients who definited Non-exon18 Mutations of PDGFRA.

This description comes directly from the study's public registry record.

Talk to the study team

Xinhua Zhang, PhD  ·  +8620-87332200  ·  zhangxinhua@mail.sysu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05461664